New drug combo vs standard for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a new targeted drug (SHR-A2009) to the standard pill aumolertinib works better than aumolertinib alone for people with advanced lung cancer that has an EGFR mutation. It's for those who haven't had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic non-small cell lung cancer with an EGFR mutation (confirmed by tissue or blood).
- You have not had any prior treatment for your advanced or recurrent lung cancer.
- You have at least one tumor that can be measured on scans.
- You are physically active (ECOG score 0 or 1) and expected to live at least 12 weeks.
- You do not have certain other cancer types, uncontrolled symptoms, severe infections, or other serious medical conditions listed in the detailed criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
This study tests a new targeted therapy, Aumolertinib, for adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has certain genetic changes (EGFR mutations). The goal is to see if the drug can shrink or slow the cancer.
This study compares two targeted pills, aumolertinib and osimertinib, as the first treatment for people with advanced EGFR-mutant lung cancer. It aims to see which one works better with fewer side effects.
This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.
This trial tests a combination of two new drugs (SHR-A1811 and AK112) for people with a specific type of advanced lung cancer that has changes in the HER2 gene. It may help those whose cancer has gotten worse after one previous treatment, or who have not yet had any treatment for advanced disease.
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.